Blood test may guide cancer care without biopsy

NCT ID NCT07673861

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovarian cancer. The test looks for genetic changes that may indicate resistance to current therapy or suggest alternative treatments. A panel of experts reviews the results to see if they can guide therapy choices, offer additional prognostic information, or eliminate the need for a tissue biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Marsden360 ctDNA test
What this could lead to
If successful, this approach could make cancer care more personalized by using a simple blood test to guide treatment decisions and reduce the need for invasive biopsies.
What could go wrong
This is an early-stage study with only 100 participants, so results may not apply to all patients. The test may not always provide useful information or change treatment plans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.